Optiscan Imaging

27/11/2023

We are pleased to advise Optiscan was featured in The Australian yesterday.

Included in the Business Review section, the article “Can the magic acronyms ‘AI’ and ‘FDA’ see Optiscan probe new heights?” was written by Tim Boreham, and covers key highlights from FY23 including clinical progress, successful capital raising and milestones in AI and Telepathology, and provides a glimpse into the future of digital pathology and precision surgery following the unveiling of our new surgical device at our AGM last week.

24/11/2023

We are delighted to be collaborating with Design + Industry in developing our new product portfolio.

D+I I are one of Australia’s leading product development consultancies, and for over 35 years have been creating world-class product design innovations for global utility.

With 260 industry awards, we look forward to perfecting and launching our new clinical device portfolio worldwide, and ensuring clinicians, health systems and patients achieve the best possible clinical outcomes with our unique real-time, non-destructive, 3D, in-vivo imaging technology at the single-cell level.

Learn more: www.optiscan.com
Learn more about D+I: www.design-industry.com.au

23/11/2023

Optiscan Imaging Ltd wishes all our US colleagues, clinicians, partners, friends, and their families a wonderful Thanksgiving.

We hope your day is filled with warmth, happiness, and the company of those closest to you.

19/11/2023

Following recent news regarding a shortage of pathologists in Australia and worldwide, we have been featured in a special report by
today.

Our pioneering slide-free, biopsy-free technology has been miniaturised and perfected to enable clinicians and pathologists to diagnose cancerous and precancerous in real-time, removing the need for time consuming tissue biopsies, sample collection, specimen processing, and traditional use of glass slides.

Optiscan (ASX:OIL) single fibre-optic miniaturised confocal endomicroscope could help alleviate Australia's growing shortage of pathologists.

31/10/2023

Optiscan Imaging Ltd has released its Quarterly Report and Appendix 4C for the quarter ended 30 September 2023.

Read: https://www.optiscan.com/investor/asx-announcements

30/10/2023

We are delighted to share coverage on our company in Stockhead today. Featured in the Health & Biotech section, "‘Diagnose on the spot’: Optiscan’s platform brings together surgeons and pathologists for better cancer outcomes" delves into our pioneering mission to establish a new standard of care in and , the market potential of our technology to & even greater opportunity to improve healthcare efficiencies, and additional context on our pursuit of FDA De Novo clearance for .

Optiscan Imaging (ASX:OIL) has developed, testing and perfected its single fibre optic miniaturised confocal endomicroscope for two decades.

23/10/2023

We are delighted to announce the appointment of Brendan Fafiani as our new Chief Operating Officer.

Mr. Fafiani brings a wealth of experience in the introduction of new technologies into existing treatment pathways, both in start-ups undergoing rapid growth and large multinational corporations.

Brendan will assume responsibility for operations at our Melbourne headquarters, and lead our operational planning, commercialisation strategy, customer and development efforts.

Read the announcement: https://www.optiscan.com/investor/asx-announcements
Learn more: www.optiscan.com

13/10/2023

Optiscan Imaging has strengthened its mission aimed at breaking into the US health market or with its “ViewnVivo” technology by putting key personnel on the ground on that country’s east and west coasts.

11/10/2023

We are delighted to announce the appointment of Tim Rowe and Shayra Leon as our new Business Development Managers for North America. Covering the East and West coast respectively, Tim and Shayra bring more than 15 years of pertinent experience and will be responsible for the growth of our ViewnVivo research device across North America.

Welcome to Optiscan Tim and Shayra.

19/09/2023

Optiscan Imaging Ltd is pleased to provide an interim readout on its Breast Cancer Intraoperative Assessment Study.

Initial data has revealed excellent correlation between our real-time CLE imaging and traditional histological analysis, providing comparable images for determination and presence of cancer, and of tumour involvement in surgical margins.

The study raises the prospect of our technology in helping to reduce recurrence rates in lumpectomy patients, reduce operating time by 25%, reduce total recurrence costs in the breast cancer space by USD$6.4 billion, and make a lasting positive impact on patient lives.

We would like to thank all collaborators involved in this study so far. Further updates will be provided in due course.

Read more: https://www.optiscan.com/investor/asx-announcements

01/09/2023

Optiscan Imaging has rounded out a dynamic year with a whopping 66 per cent revenue boost to nearly $1.7 million following the sale of its ViewnVivo research device to an American pharmaceutical company.

01/09/2023

Optiscan Imaging Ltd is pleased to release its Annual Report for the year ending 30 June 2023 today. FY23 was a year of significant transformation, with revenues increasing to $1.68m (+66%) and net cash outflows decreasing from $3.8m to $3.2m. We thank all our collaborators, shareholders, and employees for their ongoing support, and we look forward to delivering on our objectives for FY24.